Pleura and Peritoneum最新文献

{"title":"Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review.","authors":"Aditya R Kunte,&nbsp;Aamir M Parray,&nbsp;Manish S Bhandare,&nbsp;Sohan Lal Solanki","doi":"10.1515/pp-2022-0104","DOIUrl":"https://doi.org/10.1515/pp-2022-0104","url":null,"abstract":"<p><p>The role of prophylactic hyperthermic intraperitoneal chemotherapy (p-HIPEC) in serosa invasive gastric cancers without gross or microscopic peritoneal disease, to reduce the rate of peritoneal relapse is an area of ongoing research. Although p-HIPEC is effective in reducing the rate of peritoneal relapse and improving disease free and overall survival with or without adjuvant chemotherapy, when added to curative surgery in locally advanced, non-metastatic gastric cancers, the available literature is at best, heterogeneous, centre-specific and skewed. Apart from that, variations in the systemic therapy used, and the presence of the associated nodal disease further complicate this picture. To evaluate the role of p-HIPEC the PubMed, Cochrane central register of clinical trials, and the American Society of Clinical Oncology (ASCO) meeting library were searched with the search terms, \"gastric\", \"cancer\", \"hyperthermic\", \"intraperitoneal\", \"chemotherapy\", prophylactic\", \"HIPEC\" in various combinations, and a critical review of the available evidence was done. Although p-HIPEC is a promising therapy in the management of locally advanced gastric cancers, the current evidence is insufficient to recommend its inclusion into routine clinical practice. Future research should be directed towards identification of the appropriate patient subset and towards redefining its role with current peri-operative systemic therapies.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"103-115"},"PeriodicalIF":1.8,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne.","authors":"Francesco Casella,&nbsp;Maria Bencivenga,&nbsp;Riccardo Rosati,&nbsp;Uberto Romario Fumagalli,&nbsp;Daniele Marrelli,&nbsp;Fabio Pacelli,&nbsp;Antonio Macrì,&nbsp;Annibale Donini,&nbsp;Lorena Torroni,&nbsp;Michele Pavarana,&nbsp;Giovanni De Manzoni","doi":"10.1515/pp-2022-0111","DOIUrl":"https://doi.org/10.1515/pp-2022-0111","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment is palliative systemic chemotherapy with very poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in long-term benefits in selected patients. Among patients with peritoneal carcinomatosis, a distinctive subset is oligometastatic disease which is characterized by low metastatic burden. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a recent technique of intraperitoneal chemotherapy used in combination with systemic chemotherapy with promising results.</p><p><strong>Methods: </strong>PIPAC VER-One is a prospective, randomized, multicenter phase III clinical trial that aims to evaluate the effectiveness of the use of PIPAC in combination with systemic chemotherapy in patients with gastric cancer and synchronous positive peritoneal cytology and/or limited peritoneal metastases (peritoneal cancer index [PCI] ≤6). Patients will be randomized into two arms: arm A (control) treated with standard systemic chemotherapy and arm B (experimental) treated with a bidirectional scheme including PIPAC and systemic chemotherapy.</p><p><strong>Results: </strong>Primary endpoint is the secondary resectability rate. Secondary endpoints are: overall survival (OS), pregression-free survival (PFS), disease-free survival (DFS), histological response assessed both on primary tumor and peritoneal lesions, quality of life (QoL), complication rate (CTCAE v5), and incremental cost-effectiveness ratios (ICER).</p><p><strong>Conclusions: </strong>The role of PIPAC in multimodal treatment for oligometastatic gastric cancer will be investigated in this trial.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"135-141"},"PeriodicalIF":1.8,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure ‒ assessment in a novel porcine model.","authors":"Elisabeth K Petersen,&nbsp;Mats Bue,&nbsp;Christina Harlev,&nbsp;Andrea R Jørgensen,&nbsp;Anne Schmedes,&nbsp;Pelle Hanberg,&nbsp;Lone K Petersen,&nbsp;Maiken Stilling","doi":"10.1515/pp-2022-0110","DOIUrl":"https://doi.org/10.1515/pp-2022-0110","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal dissemination from intraabdominal cancers is associated with poor prognosis and rapid disease progression. Hyperthermic intraperitoneal chemotherapy (HIPEC) is an antineoplastic treatment, which has improved survival and recurrence-free survival, but little is known about the acquired chemotherapy concentrations in local tissues. The aim of this study was to assess concentrations of carboplatin during and after HIPEC treatment dynamically and simultaneously in various abdominal organ tissues by means of microdialysis in a novel porcine model.</p><p><strong>Methods: </strong>Eight pigs underwent imitation cytoreductive surgery followed by HIPEC (90 min) using a carboplatin dosage of 800 mg/m². Microdialysis catheters were placed for sampling of drug concentrations in various solid tissues: peritoneum, liver, bladder wall, mesentery and in different depths of one mm and four mm in the hepatoduodenal ligament and rectum. During and after HIPEC, dialysates and blood samples were collected over 8 h.</p><p><strong>Results: </strong>No statistically significant differences in mean AUC_0-last (range: 2,657-5,176 min·µg/mL), mean C_max (range: 10.6-26.0 µg/mL) and mean T_max (range: 105-206 min) were found between the compartments. In plasma there was a tendency towards lower measures. No difference between compartments was found for tissue penetration. At the last samples obtained (450 min) the mean carboplatin concentrations were 4.9-9.9 µg/mL across the investigated solid tissues.</p><p><strong>Conclusions: </strong>Equal carboplatin distribution in abdominal organ tissues, detectable concentrations for at least 6 h after HIPEC completion, and a carboplatin penetration depth of minimum four mm were found. The present study proposes a new HIPEC porcine model for future research.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"117-125"},"PeriodicalIF":1.8,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontmatter","authors":"","doi":"10.1515/pp-2022-frontmatter2","DOIUrl":"https://doi.org/10.1515/pp-2022-frontmatter2","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"25 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81486503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre.","authors":"Raghav Gupta,&nbsp;Nishkarsh Gupta,&nbsp;Prashant Sirohiya,&nbsp;Anuja Pandit,&nbsp;Brajesh Kumar Ratre,&nbsp;Saurabh Vig,&nbsp;Swati Bhan,&nbsp;Ram Singh,&nbsp;Balbir Kumar,&nbsp;Shweta Bhopale,&nbsp;Seema Mishra,&nbsp;Rakesh Garg,&nbsp;Sachidanand Jee Bharati,&nbsp;Vinod Kumar,&nbsp;Suryanarayana Deo,&nbsp;Sushma Bhatnagar","doi":"10.1515/pp-2022-0001","DOIUrl":"https://doi.org/10.1515/pp-2022-0001","url":null,"abstract":"<p><strong>Objectives: </strong>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with increased morbidity and mortality. We retrospectively analysed the perioperative anesthetic management in patients undergoing HIPEC surgery.</p><p><strong>Methods: </strong>After ethics approval, we reviewed the records of patients who underwent CRS/HIPEC from 2015 until 2020. We noted the peritoneal carcinomatosis index (PCI), blood loss, anastomoses done, total amount of fluid given, delta temperature and duration of surgery. These were correlated with the need for postoperative ventilation, length of ICU stay, Clavien-Dindo score and 30 day mortality.</p><p><strong>Results: </strong>Of the 180 patients reviewed, the majority were women (85%) with a mean age of 48 years who had ovarian tumors (n=114). The total amount of fluid given was associated with an increased length of ICU stay (p=0.008). Prolonged surgery resulted in increased length of ICU stay (p<0.001), need for postoperative ventilation (p=0.006) and a poor Clavien-Dindo score (p=0.039). A high PCI score correlated with increased ICU stay, 30 day mortality (p<0.001), and the need for postoperative ventilation (0.005).</p><p><strong>Conclusions: </strong>PCI, duration of surgery and blood loss were major predictors of postoperative morbidity. Additionally, the amount of fluid given and delta temperature affected patient outcome and should be individualized to the patient's needs.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"127-134"},"PeriodicalIF":1.8,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC).","authors":"Mojib Fallah,&nbsp;Sönke Detlefsen,&nbsp;Alan P Ainsworth,&nbsp;Claus W Fristrup,&nbsp;Michael B Mortensen,&nbsp;Per Pfeiffer,&nbsp;Line S Tarpgaard,&nbsp;Martin Graversen","doi":"10.1515/pp-2022-0108","DOIUrl":"https://doi.org/10.1515/pp-2022-0108","url":null,"abstract":"<p><strong>Objectives: </strong>The four-tiered peritoneal regression grading score (PRGS) is used for histological response evaluation in patients with peritoneal metastasis (PM) treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Four quadrant biopsies (QBs) from the parietal peritoneum should be assessed by PRGS, but consensus on biopsy site strategy for follow-up biopsies during repeated PIPACs is lacking. We aimed to evaluate whether there is a difference between PRGS in QBs from clips marked PM (QB-CM) compared to biopsies from PM with the visually most malignant features (worst biopsy, WB).</p><p><strong>Methods: </strong>Prospective, descriptive study. During the first PIPAC, index QBs sites were marked with metal clips. During the second PIPAC, an independent surgical oncologist selected biopsy site for WB and biopsies were taken from QB-CM and WB. One blinded pathologist evaluated all biopsies according to PRGS. From each biopsy, three step sections were stained H&E, followed by an immunostained section, and another three step sections stained H&E.</p><p><strong>Results: </strong>Thirty-four patients were included from March 2020 to May 2021. Median age 64 years. Maximum mean PRGS in QB-CM at PIPAC 1 was 3.3 (SD 1.2). Maximum mean PRGS in QB-CM at PIPAC 2 was 2.6 (SD 1.2), whereas mean PRGS in WB at PIPAC 2 was 2.4 (SD 1.3). At PIPAC 2, there was agreement between maximum PRGS from QB-CM and PRGS from WB in 21 patients. Maximum PRGS from QB-CM was higher in nine and lower in four patients, compared to PRGS from WB.</p><p><strong>Conclusions: </strong>Biopsies from QB-CM did not overestimate treatment response compared to biopsies from WB.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"143-148"},"PeriodicalIF":1.8,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of metastasis location on outcome after cytoreductive surgery and heated intraperitoneal chemotherapy.","authors":"Lise Hommelgaard,&nbsp;Jonas A Funder,&nbsp;Victor J Verwaal","doi":"10.1515/pp-2022-0106","DOIUrl":"https://doi.org/10.1515/pp-2022-0106","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to evaluate how metastases in the seven topographical regions of the simplified peritoneal cancer index (sPCI) affect the survival of patients treated with cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) from colorectal (CRC) or appendiceal cancers.</p><p><strong>Methods: </strong>Data was collected retrospectively from patient records. Abdominal regions affected by PC were identified using the histological verification of surgically removed tumours found in the electronic pathology report. Verified tumours were grouped according to the sPCI topography.</p><p><strong>Results: </strong>One hundred and eighty-three patients treated with CRS and HIPEC were included. Metastases in the small bowel had a negative impact on survival with a hazard ratio of 1.89 (p=0.005). A significantly impaired survival was also detected for patients affected by metastases in the ileocolic region (p=0.01) and in the omentum and spleen (p=0.04).</p><p><strong>Conclusions: </strong>When selecting patients for CRS and HIPEC a more cautious approach may be applied by considering the regions affected.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"149-155"},"PeriodicalIF":1.8,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium thiosulfate during cisplatin-based hyperthermic intraperitoneal chemotherapy is associated with transient hypernatraemia without clinical sequelae.","authors":"Anais Alonso,&nbsp;Winston Liauw,&nbsp;Helen Kennedy,&nbsp;Nayef A Alzahrani,&nbsp;David L Morris","doi":"10.1515/pp-2022-0107","DOIUrl":"https://doi.org/10.1515/pp-2022-0107","url":null,"abstract":"<p><strong>Objectives: </strong>Cisplatin is commonly used during intraperitoneal chemotherapy however has well-established nephrotoxic side-effects. Sodium thiosulfate is often added to cisplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) protocols to mitigate this, however evidence regarding risk of hypernatraemia is scarce as of yet.</p><p><strong>Methods: </strong>We retrospectively identified patients undergoing cytoreductive surgery (CRS) for peritoneal surface malignancies of any origin at a single high-volume unit between April 2018 and December 2020. Patients were included if they received cisplatin-based HIPEC with intravenous sodium thiosulfate. Blood tests were collected pre-surgery and then daily during admission. Hypernatraemia was defined as serum sodium >145 mmol/L. Renal impairment was defined using the RIFLE criteria.</p><p><strong>Results: </strong>Eleven CRSs met inclusion criteria, the majority of which were indicated for ovarian cancer (72.7%). One (9.1%) patient with mesothelioma received mitomycin C as an additional chemotherapy agent. The incidence of hypernatraemia was 100% but all cases were transient, with no clinical sequelae observed. The rate of AKI was 36.4%, with three (27.3%) patients classified as risk and one (9.1%) instance of failure. No long-term renal impairment was observed.</p><p><strong>Conclusions: </strong>Despite biochemical evidence of mild hypernatraemia but with the absence of clinical sequelae, sodium thiosulfate appears to be safe when used in adjunct to cisplatin-based HIPEC during CRS. These findings should be evaluated with further comparative studies. When describing renal impairment, it is important that standardisation in reporting occurs, with the RIFLE and Acute Kidney Injury Network criteria now the preferred consensus definitions.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 2","pages":"87-93"},"PeriodicalIF":1.8,"publicationDate":"2022-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40489344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.","authors":"Jolene Si Min Wong,&nbsp;Grace Hwei Ching Tan,&nbsp;Sabrina Hui Xian Cheok,&nbsp;Chin-Ann Johnny Ong,&nbsp;Claramae Shulyn Chia,&nbsp;Melissa Ching Ching Teo","doi":"10.1515/pp-2021-0150","DOIUrl":"https://doi.org/10.1515/pp-2021-0150","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal cancer index (PCI) score is a common prognostication tool in peritoneal metastases (PM). We hypothesize that the distribution of PCI score and involvement of specific regions affects survival and morbidity outcomes.</p><p><strong>Methods: </strong>Data was collected from a prospective database of patients who underwent CRS and HIPEC for PM at the National Cancer Centre Singapore. We evaluate the relationship between PCI, PCI distribution, and survival and morbidity outcomes.</p><p><strong>Results: </strong>One hundred and fifty-two patients underwent CRS and HIPEC with a median PCI score of nine (range 0-31). Median overall survival (OS) and progression free survival (PFS) were 43 and 17 months, respectively. Region six (pelvis) was most commonly involved and had the highest frequency of heavy disease burden. Presence of PM in the lower abdomen, flanks, and small bowel were associated with poorer OS (p=0.01, 0.03, <0.001) and PFS (p=0.04, 0.02, <0.001). Involvement of porta hepatitis predicted poorer OS but not PFS (p=0.03). Involvement of the gastric antrum resulted in higher rates of postoperative complications.</p><p><strong>Conclusions: </strong>The pattern of PCI distribution may be associated with varying survival and morbidity outcomes.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 2","pages":"95-102"},"PeriodicalIF":1.8,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40489345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC).","authors":"Zhenyue Li,&nbsp;Louis Choon Kit Wong,&nbsp;Rehena Sultana,&nbsp;Hui Jun Lim,&nbsp;Joey Wee-Shan Tan,&nbsp;Qiu Xuan Tan,&nbsp;Jolene Si Min Wong,&nbsp;Claramae Shulyn Chia,&nbsp;Chin-Ann Johnny Ong","doi":"10.1515/pp-2021-0154","DOIUrl":"https://doi.org/10.1515/pp-2021-0154","url":null,"abstract":"<p><strong>Background: </strong>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has recently emerged as a palliative alternative for patients with unresectable peritoneal metastasis (PM). Quality of life (QoL) has increasingly been used as an endpoint to evaluate treatment outcomes. This review aims to identify evidence on how PIPAC would impact the QoL of PM patients.</p><p><strong>Content: </strong>A systematic review was performed on articles identified from Medline, EMBASE, PsycInfo, and Web of Sciences. A meta-analysis was conducted on further selected studies. ACROBAT-NRSI was attempted to assess the risk of bias (RoB).</p><p><strong>Summary: </strong>Nine studies using the EORTC QLQ-C30 questionnaire to assess QoL after repeated PIPAC cycles were identified. Majority was found to be moderately biased and a great extent of heterogeneity was observed. Four studies on PM from either gastric cancer (GC) or epithelial ovarian cancer (EOC) were included for meta-analysis. In 31 GC patients and 104 EOC patients, QoL remained stable in 13/14 and 11/14 EORTC QLQ-C30 scales. PIPAC was inferior to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in global QoL and functioning but superior in symptom reduction.</p><p><strong>Outlook: </strong>PIPAC is a well-tolerated option for most GC and EOC patients with irresectable PM. Future trials are warranted to confirm the findings.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 2","pages":"39-49"},"PeriodicalIF":1.8,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40507159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}